Adherence to perindopril/amlodipine/atorvastatin combination according to the administration strategy

Aims To compare adherence to perindopril/amlodipine/atorvastatin combination administrated as a polypill (one pill) vs. separate tablets. Methods and results Using the healthcare utilization database of Lombardy (Italy), 1110 patients who received the perindopril/amlodipine/atorvastatin polypill during 2019–2021 were matched with 1110 patients prescribed the same combination in separate tablets or as two antihypertensive drugs in a single tablet and the lipid-lowering drug tablet separately. Adherence to treatment was assessed over the year after the first perindopril/amlodipine/atorvastatin dispensation as the proportion of the follow-up days covered by prescription (PDC). Patients with a PDC >75% and <25% were defined as highly and poorly adherent, respectively. Adherence dynamics over time were evaluated through group-based trajectory modelling. Cardiovascular-related healthcare costs were also assessed. Log-binomial regression models were fitted to estimate the risk ratio (RR) of treatment adherence associated with the administration strategy. Among the polypill and the separate-pill combination users, 60% and 18% of patients showed high adherence, respectively; the corresponding figures for the low adherence were 5% and 37%. Compared with the separate-pill combination, the polypill increased the propensity to be highly adherent to treatment by 3.29 times (95% confidence interval: 2.88–3.75) and reduced the low adherence risk (RR = 0.13, 0.10–0.18), irrespective of sex, age, comorbidities, and co-treatment burden also throughout the entire follow-up. The polypill was also associated with lower costs (€676 vs. €1068, P = 0.003). Conclusion In a real-life setting, the polypill improved treatment adherence and reduced healthcare costs compared to the corresponding separate-pill combination. These findings support current guidelines in favour of the polypill.